0UNL Stock Overview
A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.84 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.80 |
| Beta | 0.69 |
| 1 Month Change | 0% |
| 3 Month Change | -7.34% |
| 1 Year Change | -31.50% |
| 3 Year Change | -81.43% |
| 5 Year Change | -96.47% |
| Change since IPO | -98.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0UNL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 4.0% |
| 1Y | -31.5% | -7.0% | 2.1% |
Return vs Industry: 0UNL underperformed the UK Pharmaceuticals industry which returned -6.4% over the past year.
Return vs Market: 0UNL underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
| 0UNL volatility | |
|---|---|
| 0UNL Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0UNL's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0UNL's volatility change over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 61 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Fundamentals Summary
| 0UNL fundamental statistics | |
|---|---|
| Market cap | US$118.44m |
| Earnings (TTM) | -US$118.96m |
| Revenue (TTM) | US$98.43m |
1.2x
P/S Ratio-1.0x
P/E RatioIs 0UNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0UNL income statement (TTM) | |
|---|---|
| Revenue | US$98.43m |
| Cost of Revenue | US$30.69m |
| Gross Profit | US$67.74m |
| Other Expenses | US$186.70m |
| Earnings | -US$118.96m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 68.82% |
| Net Profit Margin | -120.86% |
| Debt/Equity Ratio | 151.1% |
How did 0UNL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/18 12:00 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nektar Therapeutics is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Aydin Huseynov | Benchmark Company |
| George Farmer | BMO Capital Markets Equity Research |